Generic Striant Availability
STRIANT (testosterone - tablet, extended release;buccal)
Manufacturer: ACTIENT PHARMS
Approval date: June 19, 2003
Strength(s): 30MG [RLD]
Has a generic version of Striant been approved?
No. There is currently no therapeutically equivalent version of Striant available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Striant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Bioadhesive progressive hydration tablets and methods of making and using the same
Issued: June 19, 2001
Inventor(s): Bologna; William J. & Levine; Howard L. & Cartier; Philippe & de Ziegler; Dominique
Assignee(s): Columbia Laboratories, Inc.
A bioadhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).Patent expiration dates:
- August 23, 2019✓
- August 23, 2019
- Striant Consumer Information (Drugs.com)
- Striant Consumer Information (Wolters Kluwer)
- Striant Consumer Information (Cerner Multum)
- Striant Advanced Consumer Information (Micromedex)
- Testosterone Consumer Information (Drugs.com)
- Testosterone Consumer Information (Wolters Kluwer)
- Testosterone cypionate Consumer Information (Wolters Kluwer)
- Testosterone enanthate Consumer Information (Wolters Kluwer)
- Testosterone gel Consumer Information (Wolters Kluwer)
- Testosterone patch Consumer Information (Wolters Kluwer)
- FIRST-Testosterone Consumer Information (Cerner Multum)
- Testosterone Cypionate Consumer Information (Cerner Multum)
- Testosterone Enanthate Consumer Information (Cerner Multum)
- Testosterone buccal system Consumer Information (Cerner Multum)
- Testosterone injection Consumer Information (Cerner Multum)
- Testosterone topical Consumer Information (Cerner Multum)
- Androplex Advanced Consumer Information (Micromedex)
- Testosterone Buccal Advanced Consumer Information (Micromedex)
- Testosterone Transdermal Advanced Consumer Information (Micromedex)
- Testosterone AHFS DI Monographs (ASHP)
- Testosterone Cypionate AHFS DI Monographs (ASHP)
- Testosterone Enanthate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|